Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
 Download PDFDownload PDF 

Previous Fragment    Next Fragment


Senator Xenophon, also on behalf of Senators Fierravanti-Wells and Madigan, pursuant to notice of motion not objected to as a formal motion, moved general business notice of motion no. 1080—That the Senate—

 (a) notes the concerns of key stakeholders in relation to the price reduction of chemotherapy drug Docetaxel and its potential broader impact on the treatment of cancer patients;

 (b) calls on the Government to:

  (i) negotiate with relevant bodies regarding the cost of dispensing chemotherapy drugs, and

  (ii) ensure that the result of these negotiations will allow pharmacists to continue dispensing the drug, and other chemotherapy drugs, without disrupting patients;

 (c) welcomes the policy of price disclosure of items on the Pharmaceutical Benefits Scheme; and

 (d) calls on the Government to ensure that further disruption to patients does not occur.

Statement by leave: The Parliamentary Secretary for School Education and Workplace Relations (Senator Collins), by leave, made a statement relating to the motion.

Question put and passed.